New Analyst Forecast: $CLS Given 'Overweight' Rating

CLS recently received an 'Overweight' rating from Barclays, adding to the three 'Buy' ratings from analysts in recent months, with a median price target of $140.00; however, corporate insiders have sold a significant number of shares (878,807) in the last six months, totaling an estimated $137.1 million, while institutional investors showed mixed activity in Q1 2025, with some firms significantly decreasing their positions (ARROWSTREET, FMR, FIL LTD) and others increasing (VOYA, ALKEON).

Analysis

Celestica, Inc. ($CLS) presents a mixed investment profile based on recent data. Analyst sentiment is positive, with Barclays initiating an 'Overweight' rating on June 10, 2025, and BMO Capital and RBC Capital issuing 'Outperform' ratings on May 22, 2025, and January 8, 2025, respectively, contributing to three buy ratings and zero sell ratings in recent months. The median price target from two analysts (Stifel Nicolaus and RBC Capital) in early 2025 stands at $140.00. However, this optimism is sharply contrasted by significant insider selling activity: over the past six months, insiders executed 27 sales and zero purchases, divesting 878,807 shares for an estimated $137.1 million. Notably, these sales involved key executives including the President & CEO, President, CFO, and COO. Institutional holdings also reflect divergent views in Q1 2025: while 305 institutions added $CLS to their portfolios, with VOYA Investment Management increasing its stake by 362.8% and Alkeon Capital Management establishing a new significant position, 243 institutions reduced their holdings. Major divestitures include Arrowstreet Capital decreasing its position by 89.6%, FMR LLC by 23.2%, FIL Ltd by 62.3%, and complete exits by Analog Century Management (in Q4 2024) and Vaughan Nelson Investment Management. This confluence of bullish analyst ratings against heavy insider selling and substantial institutional outflows contributes to an overall moderately negative sentiment score of -0.4 for $CLS.

Key Decisions for Investors

• Investors should weigh the positive analyst consensus and $140.00 median price target for $CLS against the considerable red flag raised by sustained, high-volume insider selling from top executives.
• Close monitoring of upcoming earnings reports and management guidance is crucial to understand the discrepancy between external analyst optimism and internal selling pressure, and to assess if company fundamentals support the bullish targets.
• Scrutinize future institutional holding disclosures for Q2 2025 to determine if the trend of large divestitures continues or if buying interest from firms like VOYA and Alkeon broadens, providing insight into evolving market conviction.